Abstract
Adrenergic mechanisms are involved in the formation of several types of pulmonary edema (PE) such as neurogenic pulmonary edema (NPE) or PE in patients with pheochromocytoma, but also in the development of pulmonary fibrosis and pulmonary hypertension. In severe cases of PE such as in the adult respiratory distress syndrome (ARDS), PE is typically accompanied by inflammation and followed by pulmonary vascular hypertrophy and pulmonary fibrosis. Norepinephrine and other adrenoceptor agonists are known to provoke activation of proinflammatory cytokines such as interleukin (IL)-1 and IL-6. These cytokines are involved both in the pathogenesis of PE and of pulmonary fibrosis. We therefore assume that adrenergic mechanisms may have an important role in the pathogenesis of pulmonary injuries characterized by edema, inflammation and fibrosis. The contribution of adrenoceptor stimulation, particularly the distinct role of α- and β-adrenergic mechanisms, to the development of PE and pulmonary fibrosis is reviewed in this paper.
Keywords: Acute lung injury, adrenergic agonists, adrenergic antagonists, isoproterenol, norepinephrine, pulmonary edema, pulmonary inflammation, pulmonary fibrosis, phenylephrine, sympathetic stimulation.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Role of α- and β-adrenergic Mechanisms in the Pathogenesis of Pulmonary Injuries Characterized by Edema, Inflammation and Fibrosis
Volume: 13 Issue: 3
Author(s): Beate Rassler
Affiliation:
Keywords: Acute lung injury, adrenergic agonists, adrenergic antagonists, isoproterenol, norepinephrine, pulmonary edema, pulmonary inflammation, pulmonary fibrosis, phenylephrine, sympathetic stimulation.
Abstract: Adrenergic mechanisms are involved in the formation of several types of pulmonary edema (PE) such as neurogenic pulmonary edema (NPE) or PE in patients with pheochromocytoma, but also in the development of pulmonary fibrosis and pulmonary hypertension. In severe cases of PE such as in the adult respiratory distress syndrome (ARDS), PE is typically accompanied by inflammation and followed by pulmonary vascular hypertrophy and pulmonary fibrosis. Norepinephrine and other adrenoceptor agonists are known to provoke activation of proinflammatory cytokines such as interleukin (IL)-1 and IL-6. These cytokines are involved both in the pathogenesis of PE and of pulmonary fibrosis. We therefore assume that adrenergic mechanisms may have an important role in the pathogenesis of pulmonary injuries characterized by edema, inflammation and fibrosis. The contribution of adrenoceptor stimulation, particularly the distinct role of α- and β-adrenergic mechanisms, to the development of PE and pulmonary fibrosis is reviewed in this paper.
Export Options
About this article
Cite this article as:
Rassler Beate, Role of α- and β-adrenergic Mechanisms in the Pathogenesis of Pulmonary Injuries Characterized by Edema, Inflammation and Fibrosis, Cardiovascular & Hematological Disorders-Drug Targets 2013; 13 (3) . https://dx.doi.org/10.2174/1871529X1303140129154602
DOI https://dx.doi.org/10.2174/1871529X1303140129154602 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Visfatin/PBEF and Atherosclerosis-Related Diseases
Current Vascular Pharmacology Coronary Artery Disease and End-Stage Renal Disease - A Clinical Perspective
Current Hypertension Reviews Perioperative Management of Patients with Down Syndrome
Current Pediatric Reviews Understanding the Concept of Chronotherapeutics in the Management of Diabetes Mellitus
Current Diabetes Reviews Vascular Dysfunction in Hypertensive Disorders
Current Hypertension Reviews An Efficient One-Pot Organocatalyzed Synthesis of Spiro[Chroman-3,6'- Furo[2,3-d]Pyrimidine]-Tetraones
Combinatorial Chemistry & High Throughput Screening Editorial: Atrial Fibrillation after Coronary Surgery: The Need for an Effective Pharmacological Prophylaxis
Current Vascular Pharmacology Potential of Selected Indian Herbs for COVID-19
Current Traditional Medicine Searching for Phytoinsulins as Cardiovascular Protector in Metabolic Syndrome
Current Pharmaceutical Design MicroRNAs in Platelet Biogenesis and Function: Implications in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology Editorial: Understanding Basic Muscle Electrophysiology While Keeping an Eye on Diseases of the Heart, Lung and Blood
Recent Patents on Cardiovascular Drug Discovery Non-Invasive Approaches to Visualize the Endothelin Axis In Vivo Using State-of-the-Art Molecular Imaging Modalities
Mini-Reviews in Medicinal Chemistry Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?
Current Cancer Drug Targets Patents in Oxidative Stress in Preeclampsia
Recent Patents on Biomarkers The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design Oxidative Stress and Cardiac Remodeling: An Updated Edge
Current Cardiology Reviews Triple Antiplatelet Therapy after PCI - Should or Could it be Done?
Cardiovascular & Hematological Disorders-Drug Targets Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry Adverse Events of Proton Pump Inhibitors: Potential Mechanisms
Current Drug Metabolism Oxidative Stress and Vascular Disease
Current Hypertension Reviews